Clinical Trial Update: The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating dalteparin for patients with knee-to-ankle fractures has completed, studying the risks of deep vein thrombosis and pulmonary embolism…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• Fragmin (dalteparin) (dalteparin)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Status: COMPLETED